Cephalon

Cephalon, Inc. was an American biopharmaceutical company co-founded in 1987 by pharmacologist Frank Baldino, Jr.,[1] neuroscientist Michael Lewis, and organic chemist James C. Kauer—all three former scientists with the DuPont Company. Baldino served as Cephalon's chairman and chief executive officer, until his death in December 2010.[1] The company's name comes from the adjective "cephalic" meaning "related to the head or brain", as it was established primarily to pursue treatments for neurodegenerative diseases.

For information about the head portion in arthropod anatomy, see Cephalon (arthropod head).

Cephalon, Inc.
TypeSubsidiary of Teva Pharmaceutical Industries
IndustryBiotechnology, Biopharmaceutical
Founded1987 (1987)
Founder
HeadquartersFrazer, Pennsylvania
Key people
J. Kevin Buchi, CEO
Productsalertness drug Provigil, the painkiller Actiq, seizure medication Gabitril[1]
Number of employees
3,726 (December 31, 2010)
Websitewww.cephalon.com

As noted by fundinguniverse.com, in its early years,

"Cephalon initially avoided involving itself in activities that would require maintaining a sales staff, managing clinical trials, and shepherding new drugs through the Food and Drug Administration (FDA) approval process. With no product to sell, Cephalon's only asset was its scientific expertise. That expertise proved sufficient to attract investors, and the company managed to fund its operations through research grants and contracts with larger pharmaceutical firms."[2]

Cephalon was first included in the Fortune 1000 list of U.S. companies based upon annual revenues for 2006. Sales revenues reached $2.8 billion in 2010, ranking Cephalon among the leading biopharmaceutical companies in the world at that time.

On May 2, 2011, Teva Pharmaceutical Industries announced it would acquire Cephalon.[3]

Product development and acquisition history

The company's early research efforts were focused on the development of IGF-1, an insulin-like growth factor, in collaboration with Chiron Corporation, toward the development of a treatment for amyotrophic lateral sclerosis (Lou Gehrig's Disease), a candidate that was never approved.

Thereafter, the company developed and commercialized products for the treatment of sleep disorders, pain,[1] addiction and cancer, establishing the "wake franchise" on the basis of Provigil (modafinil) and later, Nuvigil, the R-enantiomer of modafinil. In addition to conducting research on kinase inhibitors and other small molecules, Cephalon licensed other compounds, purchased other products, and acquired entire companies, in the latter case, including CIMA Labs, Anesta, and Laboratoire Lafon. It was from Lafon that Cephalon obtained the rights to modafinil, which it marketed under the trade name Provigil, for the treatment of excessive daytime sleepiness associated with narcolepsy, sleep apnea, and shift work sleep disorder. Sales of Provigil reached nearly one billion dollars in 2008.

In February 2009, Cephalon acquired the Australian biotechnology firm, Arana Therapeutics, which brought Cephalon its lead biologic candidate, ART621, a candidate for inflammatory diseases, and biologics for the treatment of cancers. Then, as infogrok.com noted in February 2010, "Cephalon... exercised its option to acquire Ception Therapeutics, following receipt of positive data from a clinical study in adults with eosinophilic asthma."[4] Commenting on this, Frank Baldino Jr., CEO of Cephalon, said, "The acquisition of Ception is consistent with our strategy to diversify into biologics and provides us with an important phase three asset for further development."[4]

At the time of Baldino's death in 2010, the company he had co-founded in 1987 was best known for the alertness drug Provigil, the painkiller Actiq, and the seizure disorder medication Gabitril.[1] In 2011, Cephalon agreed to acquire ChemGenex Pharmaceuticals, which would provided Cephalon with marketing rights to Omapro, a therapeutic agent for a drug-resistant leukemia, in the oncology therapeutic area.[5]

Management and locations

Longtime chief financial officer J. Kevin Buchi succeeded Baldino as CEO in 2011.[6][7] Members of the board included: venture capitalist William Egan, former COR Therapeutics CEO Vaughan Kailian, prominent healthcare economist Dr. Gail Wilensky, former SmithKline Beecham executive Dr. Martyn Greenacre, former Harvard physician and Glaxo USA head Dr. Charles Sanders and former Ambassador Kevin Moley.

The company was headquartered west of Philadelphia, in Frazer, Pennsylvania, and had research operations in nearby West Chester and manufacturing and other operations in suburban Minneapolis, Minnesota and Salt Lake City, Utah. European operations were based near Paris, France. After the acquisition of Arana, Research and Development operations continued in Sydney, Australia.

In 1999 Cephalon settled a lawsuit for $17 million in which it had faced claims that Baldino and other company executives had overstated the potential for a drug aimed at treating amyotrophic lateral sclerosis (Lou Gehrig's disease).[8] In addition, the Federal Trade Commission filed suit against Cephalon, stating that it had made "illegal deals with generic drug companies to delay generic competition to Provigil", an accusation that Cephalon has reportedly disputed.[1] In September 2008, Cephalon paid $425 million to the federal government to settle four whistleblower lawsuits and a criminal charge alleging Cephalon had marketed Actiq, Gabitril and Provigil for “off-label” (unapproved) uses.[9]

Products

Select products that Cephalon manufactured and marketed included:

References
  1. Meier, Barry (December 21, 2010). "Frank Baldino Jr., Founder of Pharmaceutical Company, Dies at 57". The New York Times. Retrieved November 21, 2018.
  2. Funding Universe Staff (November 30, 2015). "History of Cephalon, Inc". FundingUniverse.com. Retrieved November 30, 2015. As a small research house, Cephalon initially avoided involving itself in activities that would require maintaining a sales staff, managing clinical trials, and shepherding new drugs through the Food and Drug Administration (FDA) approval process. With no product to sell, Cephalon's only asset was its scientific expertise. That expertise proved sufficient to attract investors, and the company managed to fund its operations through research grants and contracts with larger pharmaceutical firms.
  3. Teva Staff (May 1, 2011). "טבע רוכשת את Cephalon תמורת 6.8 מיליארד דולר [Teva acquires Cephalon for $ 6.8 billion]" (press release). Teva.co.il. Retrieved February 10, 2020.
  4. Staff Writer (February 24, 2010). "Cephalon To Acquire Ception Therapeutics". Archived from the original on July 13, 2011. Retrieved February 10, 2020.
  5. Bennett, Simeon (March 29, 2011), "Cephalon agrees to acquire ChemGenex: Potential leukemia drug key to $230M purchase", Delaware Online, Bloomberg News, retrieved March 30, 2011
  6. Writer, By Christopher K. Hepp, Inquirer Staff (December 23, 2010). "Cephalon names J. Kevin Buchi new CEO". inquirer.com. Retrieved September 10, 2020.{{cite web}}: CS1 maint: multiple names: authors list (link)
  7. Gryta, Thomas (December 17, 2010). "Cephalon's CEO Dies While on Medical Leave". Wall Street Journal. ISSN 0099-9660. Retrieved September 10, 2020.
  8. "Westlaw Sign In | Thomson Reuters". signon.thomsonreuters.com. Retrieved February 21, 2020.
  9. Phillips and Cohen Staff (July 8, 2019) [September 29, 2008]. "Cephalon Pays $425M to Settle Whistleblower Off-label Marketing Case: Whistleblower Bruce Boise–Cephalon opioid lollipops lawsuit" (press release). Washington, D.C.: Phillips & Cohen LLP. Retrieved February 10, 2020.
This article is issued from Wikipedia. The text is licensed under Creative Commons - Attribution - Sharealike. Additional terms may apply for the media files.